There are 2949 resources available
Live Q&A - 22 September 2020 - 16:15-16:45
Presenter: Sandra Swain
Session: F. Hoffmann-La Roche - Advancing Knowledge in Early and Metastatic Triple-Negative Breast Cancer
Resources:
Webcast
Live Q&A - 23 September 2020 - 09:30-10:30
Presenter: Karim Fizazi
Session: F. Hoffmann-La Roche - Reshaping treatment paradigms for GU cancer patients: Perspectives on PI3K/AKT inhibitors in mCRPC and immunotherapy in urothelial cancer
Resources:
Webcast
Live Q&A - 28 September 2020 - 17:00-17:30
Presenter: Pasi Jänne
Session: Daiichi Sankyo -Antibody Drug Conjugates (ADCs): Advancements in the treatment of solid tumours
Resources:
Webcast
Live Q&A - 24 September 2020 - 17:00-17:30
Presenter: Javier Cortés
Session: Medscape - The HER-pathway in advanced solid tumours: Advances in targeting HER2 and future prospects for HER3
Resources:
Webcast
Improving outcomes with immunotherapy in urothelial cancer: Perspectives on the latest data
Presenter: Enrique Grande
Session: F. Hoffmann-La Roche - Reshaping treatment paradigms for GU cancer patients: Perspectives on PI3K/AKT inhibitors in mCRPC and immunotherapy in urothelial cancer
Resources:
Webcast
The changing landscape of metastatic prostate cancer: Challenges and evolving opportunities
Presenter: Karim Fizazi
Session: F. Hoffmann-La Roche - Reshaping treatment paradigms for GU cancer patients: Perspectives on PI3K/AKT inhibitors in mCRPC and immunotherapy in urothelial cancer
Resources:
Webcast
Targeting AKT: Next breaAKThrough therapies for prostate cancer care?
Presenter: Johann de Bono
Session: F. Hoffmann-La Roche - Reshaping treatment paradigms for GU cancer patients: Perspectives on PI3K/AKT inhibitors in mCRPC and immunotherapy in urothelial cancer
Resources:
Webcast
Welcome and introduction
Presenter: Karim Fizazi
Session: F. Hoffmann-La Roche - Reshaping treatment paradigms for GU cancer patients: Perspectives on PI3K/AKT inhibitors in mCRPC and immunotherapy in urothelial cancer
Resources:
Webcast
Exploring the emerging research with immuno-oncology in CSCC
Presenter: Dirk Schadendorf
Session: Sanofi Genzyme - Immune checkpoint blockade in non-melanoma skin cancer
Resources:
Webcast
Broadening horizons: new data and combinations with PARP inhibitors
Presenter: Isabelle Ray-Coquard
Session: AstraZeneca - Redefining long-term outcomes in the era of personalised medicine: Maintenance treatment in newly diagnosed ovarian cancer
Resources:
Webcast